Does VEDOLIZUMAB Cause Poor venous access? 1,043 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 1,043 reports of Poor venous access have been filed in association with VEDOLIZUMAB (ENTYVIO). This represents 1.4% of all adverse event reports for VEDOLIZUMAB.
1,043
Reports of Poor venous access with VEDOLIZUMAB
1.4%
of all VEDOLIZUMAB reports
21
Deaths
370
Hospitalizations
How Dangerous Is Poor venous access From VEDOLIZUMAB?
Of the 1,043 reports, 21 (2.0%) resulted in death, 370 (35.5%) required hospitalization, and 11 (1.1%) were considered life-threatening.
Is Poor venous access Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for VEDOLIZUMAB. However, 1,043 reports have been filed with the FAERS database.
What Other Side Effects Does VEDOLIZUMAB Cause?
Off label use (21,017)
Colitis ulcerative (13,455)
Crohn's disease (9,759)
Drug ineffective (8,424)
Diarrhoea (7,493)
Abdominal pain (6,401)
Fatigue (5,477)
Haematochezia (5,215)
Frequent bowel movements (4,527)
Arthralgia (4,028)
What Other Drugs Cause Poor venous access?
INFLIXIMAB (917)
INFLIXIMAB-DYYB (782)
ECULIZUMAB (555)
HUMAN IMMUNOGLOBULIN G (504)
NATALIZUMAB (422)
RITUXIMAB (299)
TOCILIZUMAB (287)
METHOTREXATE (257)
ABATACEPT (249)
IDURSULFASE (175)
Which VEDOLIZUMAB Alternatives Have Lower Poor venous access Risk?
VEDOLIZUMAB vs VELAGLUCERASE ALFA
VEDOLIZUMAB vs VELCADE
VEDOLIZUMAB vs VELETRI
VEDOLIZUMAB vs VELIPARIB
VEDOLIZUMAB vs VEMURAFENIB